AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) was upgraded by analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research note issued on Saturday.
Several other analysts have also recently commented on AVEO. FBR & Co reissued a “buy” rating on shares of AVEO Pharmaceuticals in a report on Saturday, April 8th. Piper Jaffray Companies reissued a “positive” rating on shares of AVEO Pharmaceuticals in a report on Friday. Finally, Zacks Investment Research cut AVEO Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, March 27th.
AVEO Pharmaceuticals (AVEO) traded up 71.75% during mid-day trading on Friday, hitting $1.25. The stock had a trading volume of 54,894,350 shares. The stock has a 50-day moving average price of $0.70 and a 200 day moving average price of $0.68. The firm’s market cap is $137.95 million. AVEO Pharmaceuticals has a 12-month low of $0.50 and a 12-month high of $1.38.
AVEO Pharmaceuticals (NASDAQ:AVEO) last posted its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported ($0.12) EPS for the quarter, meeting the consensus estimate of ($0.12). The business had revenue of $2.53 million during the quarter. AVEO Pharmaceuticals had a negative return on equity of 836.92% and a negative net margin of 728.85%. Equities analysts anticipate that AVEO Pharmaceuticals will post ($0.44) EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This story was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://sportsperspectives.com/2017/06/24/aveo-pharmaceuticals-inc-aveo-upgraded-by-valuengine-to-sell.html.
In other news, major shareholder Equity Opportunities Iv Growth acquired 6,000,000 shares of AVEO Pharmaceuticals stock in a transaction that occurred on Tuesday, March 28th. The stock was purchased at an average cost of $0.50 per share, with a total value of $3,000,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 4.70% of the company’s stock.
Institutional investors have recently modified their holdings of the company. Paloma Partners Management Co purchased a new position in shares of AVEO Pharmaceuticals during the first quarter valued at about $184,000. Geode Capital Management LLC boosted its position in shares of AVEO Pharmaceuticals by 3.9% in the first quarter. Geode Capital Management LLC now owns 315,153 shares of the biopharmaceutical company’s stock valued at $185,000 after buying an additional 11,870 shares in the last quarter. UBS Oconnor LLC purchased a new position in shares of AVEO Pharmaceuticals during the first quarter valued at about $291,000. Sabby Management LLC purchased a new position in shares of AVEO Pharmaceuticals during the first quarter valued at about $513,000. Finally, Renaissance Technologies LLC boosted its position in shares of AVEO Pharmaceuticals by 5.7% in the fourth quarter. Renaissance Technologies LLC now owns 2,743,900 shares of the biopharmaceutical company’s stock valued at $1,482,000 after buying an additional 148,500 shares in the last quarter. 50.96% of the stock is owned by hedge funds and other institutional investors.
About AVEO Pharmaceuticals
AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.
Receive News & Ratings for AVEO Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.